We invite you to participate in a multicenter retrospective observational study entitled "Use of subcutaneous immunoglobulin (SCIG 20%) and hyaluronidase-facilitated subcutaneous immunoglobulin (fSCIG) in Polish pediatric patients with primary immunodeficiency - a retrospective review", the main objective of which is to understand the administration patterns of immunoglobulins and determine the characteristics of Polish pediatric patients treated with SCIG 20% or fSCIG.
To start the study, it is necessary to sign an online agreement, so please register and follow the instructions on the computer screen.
After successful registration and electronic signing of the agreement, please log in using the credentials obtained during the account setup.
fSCIG (facilitated subcutaneous immunoglobulin) - subcutaneous immunoglobulin facilitated with hyaluronidase
SCIG (subcutaneous immunoglobulin) - subcutaneous immunoglobulin
BioStat® Company oversees the smooth progress of the study and data analysis.
Please direct any questions to the Organizer's office.
BioStat Sp. z o.o.
ul. Kowalczyka 17, 44-206 Rybnik
Tel: +48 666 069 814
Email: [email protected]
Please complete the registration form and proceed with the study.
Takeda Pharma sp. z o.o.
ul. Prosta 68, 00-838 Warsaw
Tel: +48 22 608 13 00/01
Fax: +48 22 608 13 03
Please log in using the credentials received after online agreement.